TABLE 3.
Mutation frequencies changing gradually for resistance-related mutations as detected by WGS
| Patient no. | Acquired phenotypic drug resistancea | Acquired genetic drug resistance | Resistant mutations | Frequency of resistant mutations |
|---|---|---|---|---|
| 2 | PZA | pncA | L85R | 0 ↗ 15.5 ↘ 0 |
| 166c in | 0 ↗ 35.7 ↘ 0 | |||
| 3 | MFX2.0 | gyrA | A90V | 98.2 ↘ 83.5 ↘ 0 |
| D94N | 0 ↗ 81.7 ↗ 84.6 | |||
| 5 | / | ethA | S57P | 54.9 ↘ 0 ↗ 99.6 |
| Y461stop | 34.9 ↗ 99.2 ↘ 0 | |||
| 7 | / | ethA | S183R | 42.1 ↘ 15.1 ↘ 0 → 0 |
| Q254P | 0 ↗ 59.9 ↘ 0 → 0 | |||
| Y286stop | 34.3 ↘ 23.6 ↗ 99.8 → 99.8 | |||
| 8 | CS | alr | c-13g | 0 → 0 → 0 ↗ 83.6 |
| L1134 | 0 → 0 → 0 ↗ 15.0 | |||
| Y388D | 0 → 0 → 0 ↗ 44.4 | |||
| PTO | ethA | W116C | 0 ↗ 29.6 ↗ 98.2 → 98.2 | |
| 9 | MFX2.0 | gyrA | D94H | 0 → 0 → 22.8 ↘ 0 → 0 |
| gyrB | E501V | 0 → 0 ↗ 24.3 ↗ 47.1 ↘ 29.6 | ||
| E501D | 0 → 0 → 0 ↗ 48.7 ↗ 51.3 | |||
| 11 | SLID | rrs | a1401g | 0 ↗ 79.5 ↗ 99.7 |
| 17 | PTO | ethA | F48V | 0 ↗ 88.7 ↘ 62.2 ↘ 20.9 |
| 694tc_in | 0 ↗ 10.9 ↗ 28.2 ↗ 82.4 | |||
| 19 | MFX2.0 | gyrB | A504V | 0 ↗ 24.8 ↗ 86.0 |
a
SLID, second-line injectable drug; PZA, pyrazinamide; MFX, moxifloxacin; PTO, prothionamide; CS, cycloserine; /, not applicable.